Cornelissen F, Van den Bossche H
Chemotherapy. 1983;29(6):419-27. doi: 10.1159/000238230.
The antibacterial activity of a combination of miconazole with bacitracin against Staphylococcus epidermidis or Staphylococcus aureus, was greater than the sum of the effects observed with the two drugs independently. Since no uptake changes were observed, this synergism may originate from a combined effect of miconazole and bacitracin on the biosynthesis of the carrier lipid, undecaprenyl-phosphate, resulting in an impairment of cell wall integrity. The synergism between these drugs and polymyxin B may be due to an increased accessibility of the cell membrane to polymyxin B. Miconazole and bacitracin, alone or in combination, are completely inactive against Escherichia coli. Since polymyxin B disturbs the permeability barrier and stimulates the uptake of miconazole, the synergism of polymyxin B, miconazole and bacitracin may originate from the ability of miconazole and bacitracin to penetrate the bacterial membranes in the presence of polymyxin B.
咪康唑与杆菌肽联合使用对表皮葡萄球菌或金黄色葡萄球菌的抗菌活性，大于单独使用这两种药物时观察到的效果之和。由于未观察到摄取变化，这种协同作用可能源于咪康唑和杆菌肽对载体脂质十一异戊烯磷酸生物合成的联合作用，导致细胞壁完整性受损。这些药物与多粘菌素B之间的协同作用可能是由于细胞膜对多粘菌素B的可及性增加。咪康唑和杆菌肽单独或联合使用对大肠杆菌完全无活性。由于多粘菌素B扰乱通透性屏障并刺激咪康唑的摄取，多粘菌素B、咪康唑和杆菌肽的协同作用可能源于咪康唑和杆菌肽在多粘菌素B存在下穿透细菌膜的能力。
